We navigate you through the healthcare market.

Consultancy for medical device companies to support Market Access of innovative medical products.

Who we are

 

Healthcare Heads specializes in delivering tailored consultancy services in Reimbursement and Market Access exclusively designed for medical companies targeting the German healthcare market.

Our mastery of Market Access spans across pivotal areas encompassing Reimbursement, Economics, Evidence and External Affairs. These key focal points empower us to provide you with holistic and all-encompassing solutions.

Distinguished by an unparalleled fusion of expertise and an extensive track record within the German healthcare realm, we stand as your foremost partner in shaping Reimbursement and Market Access strategies and ensuring their seamless operational integration.

In collaboration with you, we surmount barriers that impede market entry, unlocking pathways to connect your pioneering technology with a broader spectrum of patients. Let us embark on this journey together, unraveling the full potential of your innovation.

E-Mail: info@healthcareheads.com

Phone: +49 431 800 147 0

 

Turning complex coding and reimbursement information into a tool for your sales team.

Short-Term Reimbursement Decision for Clesrovimab: ZE191 has been added to the 2026 DRG Catalog. This adjustment demonstrates how dynamically reimbursement pathways can evolve in the hospital market.

Hospital planning must take into account the long-term financing of modern medical technology.

Safety notice

PHP updates are completed. No data was compromised.

New same-day reimbursement starting in 2027 will bring significant changes to the therapy reimbursement model in Germany

The "Gemeinsame Bundesausschuss” (Joint Federal Committee) has clarified that the expanded mandatory procedure under Section 137h of Book V of the Social Code (SGB V) does not yet apply to the NUB application round 2026-2027.

€50 billion to finance the structural changes in hospital care required by the hospital reform. The new funding guideline provides clarity for investments and structural transformation.

For the next eight weeks you have the opportunity to receive reimbursement for your innovative therapy though the NUB application process

Now is the right time to plan coding brochures, NUB strategies and applications for the further development of the aG-DRG system for 2027.

Subscribe to the Healthcare Heads newsletter

with topics of Market Access and Reimbursement in Germany.

Don't miss any of the latest developments and be among the first to receive relevant information from the areas of market access and reimbursement in Germany.

Privacy policy
Marketing von